Tsun Sean Law, MD, MBA

CEO and Board Member

Dr. Tsun Sean Law, MD, MBA, is a South Florida–based orthopedic medicine physician specializing in hip and knee osteoarthritis, with a focus on orthobiologics and regenerative medicine. He serves as Director of Clinical Research at HSS Florida, where he leads studies on orthobiologic therapies, such as microfragmented adipose tissue, aiming to enhance treatment options for osteoarthritis. Dr. Law has been featured in Medscape, where he discussed the current landscape and challenges of orthobiologic treatments .

In addition to his clinical work, Dr. Law holds several leadership positions in the nuclear energy sector. He serves on the Board of Directors at NANO Nuclear Energy (Nasdaq: NNE) and LIS Technologies Inc. His involvement in these companies reflects his commitment to advancing medical innovation and healthcare investments.

Dr. Law’s research spans the integration of robotic and sensor technologies in orthopedic care to orthobiologics in regenerative medicine. His work has been published in numerous peer-reviewed journals and presented at both national and international conferences .

Omar K. Sial, PhD

Chief Scientific Officer

Dr. Sial is a distinguished researcher whose work integrates neuroscience, immunology, and genetics. With over 13 years of experience in preclinical research and pharmaceutical drug development, he brings extensive expertise in advancing novel drug candidates from mechanistic exploration to translational biopharmaceutical applications. His contributions have helped bridge the gap between early discovery and real-world therapeutic innovation.

Throughout his career, Dr. Sial has held key positions across academia and industry, where most recently he led analytical and process development initiatives and contributed to the design, optimization, and validation of biologic formulations. As a postdoctoral associate at the UF Scripps Biomedical Research Institute, he investigated orphan receptor biology and the intra- and extracellular mechanisms of signal transduction—work that informs his current focus on molecular communication mediated by extracellular vesicles. Earlier in his career, he was involved with research at the Icahn School of Medicine at Mount Sinai, studying the structure and function of the extracellular matrix within the brain, and consulted for Stream Biomedical.

Michael Milligan, MD, MBA, CAQSM

Chief Medical Officer

Dr. Michael Milligan brings more than 25 years of clinical medicine, leadership, and research experience to Human Continuum Inc. Dr. Milligan is fellowship trained and certified in sports medicine and board certified in family medicine. Dr. Milligan brings a vast experience in sports medicine, sports injuries, and musculoskeletal and orthopedic medicine. Currently Dr. Milligan is program director for primary sports medicine, regenerative medicine, and for business strategy for HSS Florida. Prior to joining HSS FL, he was program director of primary care sports medicine and medical director of sports medicine outreach for the Andrews Institute in Pensacola, Florida. During his time at the Andrews Institute Dr. Milligan led many initiatives including value metric based health care programs, service line coordinations to improve viability during implementation of the CMS bundled payment program for joint replacement, and development of an integrated multidisciplinary spine program.

Dr. Milligan came to the Andrews Institute after a decade in college athletics serving as the Head Team Physician and Medical Director of all athletic programs at University of Nevada Las Vegas and later as the Head Team Physician and Medical Director of Northwestern University Athletics and Health Services Sports Medicine. During his tenure in Division I college athletics not only was Dr. Milligan, the day-to-day physician responsible for all athlete healthcare, he also led the development of many innovative programs both within and outside of the confines of the Division I athletic environment, including wellness programs, research endeavors, and performance improvement. Dr. Milligan was a member of the Department of Orthopedics and Northwestern Medicine and a member of the Department of Family Medicine at the University of Nevada School of Medicine Las Vegas.

Dr. Martin W. Roche

Scientific Medical Advisory Team

Dr. Martin W. Roche is a distinguished orthopedic surgeon and a prominent leader in the field of robotic and sensor-assisted knee surgery, currently serving as the Director of Arthroplasty at HSS Florida in West Palm Beach. A native of Ireland, Dr. Roche completed his orthopedic training at the University of Miami and has been practicing in South Florida since 1996. He is internationally recognized for performing the world’s first sensor-assisted and robotic-assisted knee surgeries, and is a pioneer in minimally invasive joint replacement techniques.

Dr. Roche is also the clinical developer of the MakoSurgical Knee System and the founder of Orthosensor Inc., which develops advanced sensors to enhance patient care in orthopedics. He has trained hundreds of surgeons, holds multiple patents, and is widely published, dedicating his career to advancing surgical outcomes through cutting-edge technology.

Ryan Simovitch, MD

Medical Advisory Team

With nearly two decades of experience as an Orthopaedic shoulder surgeon, Dr. Ryan Simovitch has been an innovator, a mentor, and a passionate pursuer of research related to outcome optimization after shoulder surgery. In his pursuit of surgical outcome optimization as well as nonoperative options for treating various shoulder conditions, he has embraced biologics looking for ways to harness the body’s own capacity to heal and regenerate damaged tissue.

Dr. Simovitch is currently the Director of the Shoulder Division at HSS FL as well as the Co-Medical Director over HSS FL. While his early focus on research centred on developing gene therapy for a metabolic disorder – Fabry Disease, his focus has evolved over the years to developing and utilizing novel techniques to treat rotator cuff tears and arthritis in the shoulder.

Dr. Simovitch completed his undergraduate education at Duke University. Upon completing medical school at the Chicago Medical School, Dr. Simovitch matriculated for his Orthopaedic Surgery Residency at Duke University Medical Center. In 2004, Dr. Simovitch was awarded the prestigious Intercontinental Harvard Shoulder Fellowship allowing him to complete his shoulder surgery subspecialized training at the Massachusetts General Hospital in Boston, MA and Uniklinik Balgrist in Zurich, Switzerland. Dr. Simovitch has received numerous awards for his presentation of novel research studies at multiple national and international society meetings. In 2021, he was recognized as being the lead author of one of the fifty most frequently cited publications of all time in shoulder arthroplasty research.